Biolinco was founded in 2023 by Kent Rapp and Kevin Wen, PhD researchers at Johns Hopkins University in Baltimore, with a clear-eyed view of a broken process: current cell line development workflows evaluate only a handful of clones, forcing critical decisions with incomplete data. The platform draws on years of research into DNA barcoding and multi-omic characterization of CHO cells — giving biopharmaceutical companies the depth of information they need to select the right clone, the first time.